相关临床试验
91
5 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1966
进行中（未招募）
2
2.2%
已完成
62
68.1%
尚未招募
3
3.3%
招募中
12
13.2%
暂停
1
1.1%
终止
4
4.4%
Unknown
6
6.6%
撤回
1
1.1%
暂无批准数据
- An international study analyzing data from nearly 80,000 infants found that approximately 10% of variation in toddler activity levels can be explained by common genetic variants. - The genetic markers associated with early activity levels strongly overlap with those known to influence ADHD risk later in childhood and adulthood. - Researchers identified the RHEBL1 gene, where specific markers linked to lower toddler activity also appear to increase gene activity in the brain's cortex. - The findings, published in Nature Human Behaviour, open new possibilities for earlier identification and intervention for children at risk of ADHD-like behaviors.
- Forskolin, a natural plant compound, demonstrates dual anti-leukemic activity by directly slowing cancer cell growth and enhancing chemotherapy effectiveness in KMT2A-rearranged AML. - The compound activates Protein Phosphatase 2A and reduces cancer-linked gene activity while also inhibiting P-glycoprotein 1 to improve daunorubicin retention in leukemia cells. - Research from the University of Surrey suggests combining forskolin with daunorubicin could enable lower chemotherapy doses and reduce severe side effects. - The findings, published in the British Journal of Pharmacology, represent a collaborative effort to develop kinder, more effective treatments for one of the most aggressive cancer types.
- Researchers from the University of Surrey, Chester Zoo, and the Animal and Plant Health Agency successfully developed and tested the world's first vaccine against elephant endotheliotropic herpesvirus (EEHV), a leading killer of young Asian elephants. - The proof-of-concept study published in Nature Communications demonstrated the vaccine's safety in adult elephants with no adverse side effects while triggering strong antiviral immune responses through CD4+ and CD8+ T cell activation. - The two-step vaccination protocol used viral vector delivery followed by protein boosters, with whole transcriptome sequencing revealing comprehensive immune pathway activation for the first time in elephants. - The breakthrough offers hope for protecting elephant calves, the most vulnerable population, and could significantly impact conservation breeding programs worldwide by reducing EEHV-related mortality.
- A new clinical trial published in Lancet Psychiatry demonstrates that mindfulness-based cognitive therapy (MBCT) significantly improves symptoms in patients with difficult-to-treat depression compared to standard care. - The eight-week MBCT program delivered via videoconference was found to be cost-effective at less than £100 per person, potentially saving healthcare systems money while providing a viable treatment option for patients who haven't responded to conventional therapies. - Researchers from the University of Surrey, University of Exeter, and University of Sussex report that MBCT's effectiveness is comparable to antidepressants, offering new hope for the approximately 50% of depression patients who remain symptomatic after completing standard psychological treatments.
- Researchers have discovered that amlodipine, a common blood pressure medication, significantly reduced hyperactivity and impulsivity in preclinical ADHD models using zebrafish studies. - Genetic analysis revealed important connections between ADHD and calcium channels targeted by amlodipine, with UK patient data showing reduced mood swings and risk-taking behavior in individuals taking the medication. - The established safety profile and existing approval of amlodipine could accelerate its potential repurposing as an alternative ADHD treatment option, offering advantages over traditional stimulant medications.
- Moderna has launched 23 clinical trials across 110 UK sites since 2021, becoming the largest industry sponsor with 20% of all industry-sponsored trial participants in 2023/24. - The new Moderna Innovation and Technology Centre in Oxfordshire is nearing completion, with capabilities to produce 250 million vaccine doses annually and house state-of-the-art research laboratories. - Through strategic partnerships, Moderna has initiated mRNA research collaborations with four UK universities and expanded trial accessibility through innovative recruitment strategies including pharmacy partnerships.
- A novel drug candidate, NK2R, has demonstrated weight loss effects in preclinical studies by targeting appetite and increasing calorie burning. - Unlike semaglutide (Ozempic), NK2R appears to spare muscle mass during weight loss, potentially offering a significant advantage. - The drug acts on a different neural circuit than GLP-1 agonists, targeting the neurokinin 2 receptor to influence blood sugar, body weight, and cholesterol. - Human clinical trials are planned within the next two years to assess the safety and efficacy of NK2R in overweight individuals.
